» Authors » Sadao Hikishima

Sadao Hikishima

Explore the profile of Sadao Hikishima including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 134
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Muramatsu D, Watanabe-Nakayama T, Tsuji M, Umeda K, Hikishima S, Nakano H, et al.
FASEB J . 2025 Feb; 39(3):e70382. PMID: 39921439
Alzheimer's disease (AD) is the most prevalent age-related neurodegenerative disorder, mainly characterized by amyloid β (Aβ) accumulation in the brain. Numerous new agents are currently undergoing clinical trials as disease-modifying...
2.
Noguchi-Shinohara M, Sakashita Y, Nakano H, Muramatsu D, Hikishima S, Komatsu J, et al.
J Prev Alzheimers Dis . 2025 Jan; 12(1):100003. PMID: 39800463
Plasma amyloid-β (Aβ) markers are significant predictors of Aβ pathology. However, their prognostic value for cognition in patients with Alzheimer's disease (AD) is unknown. We compared plasma amyloid-β precursor protein...
3.
Nakano H, Hikishima S, Mori M, Minamikawa J, Muramatsu D, Sakashita Y, et al.
Neurobiol Dis . 2024 Dec; 205():106775. PMID: 39719197
The accumulation of amyloid β-proteins (Aβ) in the extracellular space, forming insoluble plaques, is a primary pathological process underlying Alzheimer's disease (AD). Among the various Aβ species that appear during...
4.
Noguchi-Shinohara M, Murakami H, Sakashita Y, Mori Y, Komatsu J, Muramatsu D, et al.
Parkinsonism Relat Disord . 2023 May; 111:105445. PMID: 37201326
No blood biomarkers which can identify Alzheimer's disease pathology in Lewy body disease (LBD) have ever been established. We showed that the plasma amyloid-β (Aβ) /Aβ ratio was significantly decreased...
5.
Hikishima S, Sakai K, Akagi A, Yamaguchi H, Shibata S, Hayashi K, et al.
Intern Med . 2022 Mar; 61(15):2347-2351. PMID: 35283385
We herein report a 44-year-old Japanese man with hereditary transthyretin amyloidosis (ATTRv amyloidosis) harboring the variant Leu58Arg (p.Leu78Arg) in TTR in whom we conducted an observational study with liver transplantation...
6.
Wielgus-Kutrowska B, Breer K, Hashimoto M, Hikishima S, Yokomatsu T, Narczyk M, et al.
Bioorg Med Chem . 2012 Oct; 20(22):6758-69. PMID: 23040896
Transition-state analogue inhibitors, immucillins, were reported to bind to trimeric purine nucleoside phosphorylase (PNP) with the stoichiometry of one molecule per enzyme trimer [Miles, R. W.; Tyler, P. C.; Furneaux,...
7.
Breer K, Glavas-Obrovac L, Suver M, Hikishima S, Hashimoto M, Yokomatsu T, et al.
FEBS J . 2010 Mar; 277(7):1747-60. PMID: 20193043
Genetic deficiency of purine nucleoside phosphorylase (PNP; EC 2.4.2.1) activity leads to a severe selective disorder of T-cell function. Therefore, potent inhibitors of mammalian PNP are expected to act as...
8.
Hikishima S, Hashimoto M, Magnowska L, Bzowska A, Yokomatsu T
Bioorg Med Chem . 2010 Mar; 18(6):2275-2284. PMID: 20189401
9-(5',5'-Difluoro-5'-phosphonopentyl)-9-deazaguanine (DFPP-DG) was designed as a multi-substrate analogue inhibitor against purine nucleoside phosphorylase (PNP) on the basis of X-ray crystallographic data obtained for a binary complex of 9-(5',5'-difluoro-5'-phosphonopentyl)guanine (DFPP-G) with...
9.
Glavas-Obrovac L, Suver M, Hikishima S, Hashimoto M, Yokomatsu T, Magnowska L, et al.
Chem Biol Drug Des . 2010 Jan; 75(4):392-9. PMID: 20102369
Potent inhibitors of purine nucleoside phosphorylase (PNP) are expected to act as selective agents against T-cell tumours. Five compounds with guanine, three with hypoxanthine, and five with 9-deazaguanine, all connected...
10.
Breer K, Wielgus-Kutrowska B, Girstun A, Staron K, Hashimoto M, Hikishima S, et al.
Biochem Biophys Res Commun . 2009 Dec; 391(2):1203-9. PMID: 20005207
Calf purine nucleoside phosphorylase (PNP) was overexpressed in Escherichia coli. The basic kinetic parameters of recombinant PNP were found to be similar to the values published previously for non-recombinant PNP...